2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/14/18UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments  
Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical Trial of UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) Conference Call Today at 8:30 a.m. Eastern Time RA’ANANA, Israel and NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company... 
Printer Friendly Version
08/08/18UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization RA’ANANA, Israel, and NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company today announced that Peter P. Pfreundschuh has been appointed as Chief Financial Officer (CFO) effective August 20, 2018.  Mr. Pfreundschuh brings to Uro... 
Printer Friendly Version
08/07/18UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second quarter 2018 financial results on Tuesday, August 14, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time. Audio Webcast The webcast will be made available on the Investors section of the Company’s website at h... 
Printer Friendly Version
07/11/18UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has Potential to Become the First Front Line Non-Surgical Therapy for Patients with LG NMIBC RA’ANANA, Israel and NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it submitted to the U.S. Food and Drug Administration (FDA) an In... 
Printer Friendly Version
07/10/18UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors  
Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology RA’ANANA, Israel and NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Shawn Cline Tomasello has been appointed to its Board of Directors. Ms. Tomasello i... 
Printer Friendly Version
06/13/18UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
RA’ANANA, Israel and NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun, MD, FACS, UroGen’s Chairman, will be honored with the prestigious EY Master Entrepreneur Award during the Entrepreneur of the Year 2018 Awards Gala on Thursday, June 14, 2018 in Los Angeles. The Master Entrepreneur ... 
Printer Friendly Version
06/05/18UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
RA’ANANA, Israel, and NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that Stephen Mullennix, UroGen’s Chief Operating Officer, will become Interim Chief Financial Officer, replacing Gary Titus. Mr. Titus will remain as a consultant during the transition. “Gary played an important role in the early stages of building UroGen and in par... 
Printer Friendly Version
05/29/18UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference
RA’ANANA, Israel and NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 11:00AM Eastern Time in New York, NY. A live audio webcast of the event will be available on the Invest... 
Printer Friendly Version
05/21/18UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
Interim Results Showed Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade UTUC CRs to Date Remain Durable at Three, Six and Nine-Month Follow-Up RA’ANANA, Israel and NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced new findings from an interim analysis of the ongoing pivotal Phase 3 OLYMP... 
Printer Friendly Version
05/15/18UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA) Annual Meeting on May 21, 2018 Submission of UGN-101 New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) Expected in Q1 2019 UGN-102 (VesiGel™) Investigational New Drug (IND) Application Planned for Mid-2018 Conference Call Today at 8:30 a.m. Eastern Time RA’ANANA, Isr... 
Printer Friendly Version
05/08/18UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2018 financial results on Tuesday, May 15, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time. Audio Webcast The webcast will be made available on the Investors section of the Company’s website at http://... 
Printer Friendly Version
04/24/18UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
RA’ANANA, Israel and NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that members of management and the Board of Directors will ring the Nasdaq stock market opening bell on Wednesday, April 25, 2018. “We are proud to have been one of the top performing IPOs of 2017 in the biotech space and look forward t... 
Printer Friendly Version
04/03/18UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
RA’ANANA, Israel and NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data presentation from an interim analysis of the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (MitoGel™), an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cance... 
Printer Friendly Version
03/15/18UroGen Reports Fourth Quarter and Full Year 2017 Financial Results
Presentation of MitoGel™ Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting Conference Call to be Held Today at 8:30am ET RA’ANANA, ISRAEL and NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial results for the f... 
Printer Friendly Version
03/08/18UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time. Audio Webcast The webcast will be made available on the Investors section of the Company... 
Printer Friendly Version
03/07/18UroGen to Present at March 2018 Investor Conferences
RA’ANANA, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018: Cowen & Company 38th Annual Health Care Conference Tuesday, March 13 8:00AM Eastern Time Boston, MA Oppenheimer 28th Annual Healthcare Conference Wednesday, March 21 9:45AM Eastern Time New York, NY A live audio webcast of each event will be available on the Investors section of ... 
Printer Friendly Version
02/14/18UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
RA’ANANA, Israel and NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Stephen Mullennix as Chief Operating Officer with overall responsibility for the Company’s operations.  Mr. Mullennix will join the senior management team and will report to Ron Bentsur, UroGen’s Chief Executive Officer. ... 
Printer Friendly Version
01/23/18UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
RA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share. In addition, the underwriters exercised their option to purchase an additional 219,512 ordinary shares at the public offering p... 
Printer Friendly Version
01/18/18UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
RA'ANANA, Israel and NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share for gross proceeds of approximately $60.0 million, before deducting underwriting discounts and commissions and estimated offerin... 
Printer Friendly Version
01/16/18UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
RA’ANANA, Israel and NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) in connection with a public offering of 1,135,847 ordinary shares. The company intends to grant the underwriters a 30-day option to pu... 
Printer Friendly Version
01/08/18UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
Kate Bechtold, Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations RA’ANANA, Israel, and NEW YORK, Jan. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Christine Cassiano, formerly the top communications executive at Kit... 
Printer Friendly Version
01/02/18UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
RA’ANANA, Israel and NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11, 2018 at 9:00 a.m. PST. A live audio webcast of the presentation will... 
Printer Friendly Version